Concepedia

Vidula Naik

VN

Statistics

Publications

7

Citations

196

H-Index

7

Active since

2019

Affiliations

Gilead Sciences (United States)(Current)

Shushrusha Citizens' Co-operative Hospital

Yale University

Vidula Naik is an author at Gilead Sciences (United States) specializing in antiviral therapy, antiviral drug resistance, and molecular virology.

Publications per year

2019–2026

7

Publications

7

Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir

Nicolas Margot, Vidula Naik, Laurie A. VanderVeen et al. · The Journal of Infectious Diseases · 2022 · 57 citations

, , +17

Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study

Nicolas Margot, Laurie A. VanderVeen, Vidula Naik et al. · Journal of Antimicrobial Chemotherapy · 2022 · 54 citations

, , +17

Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years

Nicolas Margot, Vamshi Jogiraju, Nina Pennetzdorfer et al. · The Journal of Infectious Diseases · 2025 · 28 citations

, , +17

Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA

Nicolas Margot, Nina Pennetzdorfer, Vidula Naik et al. · Antiviral Therapy · 2023 · 23 citations · Full text

, , +17

Substantial Remission in Subacute Sclerosing Panencephalitis by Following the Ketogenic Diet: A Case Report

Janak Nathan, Dhanashri Khedekar Kale, Vidula Naik et al. · Cureus · 2019 · 14 citations · Full text

, , +13

1–5 of 7